RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

Launched by NORTHWESTERN UNIVERSITY · Jul 10, 2023

Keywords

ClinConnect Summary

This small, early-phase study at Northwestern University is testing whether giving a one-time TNF-alpha inhibitor (Etanercept) right before a lung transplant can help protect kidney function and reduce problems with the new lung. About 20 adults who are planning to have a lung transplant at Northwestern will be randomly assigned to receive either Etanercept (25 mg, given as a quick shot before transplant) plus standard care, or standard care alone. Participants must be 18 or older and able to consent, and they must be planning to have a lung transplant at Northwestern. People who have previously or recently used TNF inhibitors, or who have a condition that would make participation unsafe, are not eligible.

If you join, you’ll receive one dose of Etanercept just before the transplant and then go on with normal post-transplant care. Researchers will track how well your kidneys work immediately after transplant, during the first week and up to 30 days after transplant, by checking kidney function tests. They’ll also look at other important outcomes like how well the new lung works in the first few days, how long you stay in the ICU, how long you need a ventilator, and overall survival at 30 days, 90 days, and one year. The study is currently enrolling and expects to finish around April 2025. If you want more details, ask your transplant team or the study’s principal investigator, Chitaru Kurihara, MD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Planning to undergo transplantation of the lung at Northwestern Memorial Hospital.
• • Willing and able to read, understand, and be capable of giving informed consent.
• Exclusion Criteria:
• • Previous or current use of TNFa antibody.
• • Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.